11 apr: 2nd UPDATE: Biomet 3Q Loss Widens On Charges; Sales Grow 5%
11 apr: States Could See More Tobacco Payments This Year
11-04-2012 23:21:00

Quest Diagnostics Names Rusckowski As President, CEO

Relateret indhold

DOW JONES NEWSWIRES

Quest Diagnostics Inc. (DGX) named Royal Philips Electronics NV (PHG, PHIA.AE) executive Stephen Rusckowski as its new president and chief executive, ending a six-month search for a successor to current CEO Surya Mohapatra.

Rusckowski's appointment is effective May 1 and he will also join the company's board. Rusckowski has served as CEO of Philips Healthcare, Royal Philips' largest unit, since 2006.

The management change could mark a new course for the company. Some decisions Quest made under Mohapatra--such as the acquisition of diagnostics company AmeriPath Inc. and an expansion into India--have been criticized by analysts.

Quest, the largest diagnostic-testing company in the U.S. by revenue, had been hurt by a decline in doctor-office visits as consumers have reined in their health-care spending since the recession. Last year, the company unveiled a restructuring initiative to reduce its costs by $500 million over the next three years to help it meet profit targets. In October, the company initiated a search for a replacement for Mohapatra, who held the titles of chairman, president and CEO.

Quest also appointed lead director Daniel C. Stanzione as its new non-executive chairman.

"Steve Rusckowski is uniquely qualified to be chief executive officer of Quest Diagnostics," Stanzione said. "He has built an enviable track record in health care by successfully driving growth, both organically and through disciplined, effective acquisitions. His emphasis on operational excellence has enabled him to deliver consistently impressive results."

In January, Quest reported its fourth-quarter earnings rose 14% as the company saw higher testing revenue and improved margins.

Shares closed at $59.57 Wednesday and were unchanged after hours. The stock is up 2.6% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

(END) Dow Jones Newswires

April 11, 2012 17:21 ET (21:21 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Maersk Line-chef tager på charmeoffensiv i Kina

19-09-2014 15:47:03
Den administrerende direktør for Maersk Line, Søren Skou, har besøgt de kinesiske myndigheder i et forsøg på at skaffe opbakning til en ny shipping-alliance med..

Novo/Sydbank: Novo sidder tungt på diabetes-tronen

19-09-2014 12:17:21
Sydbank fastholder sin anbefaling af Novo Nordisk-aktien til trods for, at den amerikanske lægemiddelstyrelse, FDA, torsdag aften har godkendt Novo-konkurrenten..

Novo: Nygodkendt diabetesmiddel giver lynhurtigt effekt

19-09-2014 11:31:02
Novo Nordisks nye kombinationspræparat til behandling af type 2 diabetes, Xultophy, yder allerede efter fire uger en betydelig blodsukkerkontrol.Det fremgår af ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas/Jyske: Svagt momentum bag lavere kursmål
2
Aktier/åbning: C20 styrer mod rekord efter skotsk afstemning
3
Novo får godkendt kombinationsmidlet Ideglira i EU
4
Aktier/tendens: Skotsk afstemning løfter stemningen
5
Aktier/middag: Skotterne sender Vestas og C20 til vejrs

Relaterede aktiekurser

Philips KON 23,74 0,7% Stigning i aktiekurs
Koninklijke Philips N.V. 30,54 0,4% Stigning i aktiekurs
Quest Diagnostics Inc 63,41 0,6% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
19. september 2014 21:53:24
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140919.1 - EUROWEB7 - 2014-09-19 21:53:24 - 2014-09-19 21:53:24 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x